Xvivo Perfusion AB
STO:XVIVO
Xvivo Perfusion AB
STO:XVIVO
Price:
181.6
SEK
-3.3%
Market Cap:
kr5.7B
Relative Value
The Relative Value of one
XVIVO
stock under the Base Case scenario is
77.15
SEK.
Compared to the current market price of 181.6 SEK,
Xvivo Perfusion AB
is
Overvalued by 58%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
XVIVO
Relative Value
Base Case
77.15
SEK
Overvaluation 58%
Multiples Across Competitors
XVIVO Competitors Multiples
Xvivo Perfusion AB Competitors
Xvivo Perfusion AB Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
|
Xvivo Perfusion AB
STO:XVIVO
|
5.9B SEK | 7 | 227.3 | 62.7 | 62.7 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.5T JPY | 10.4 | 38 | 27.5 | 33 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
55.5B USD | 0 | 0 | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 3.6 | 38.3 | 14.7 | 28.6 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
100.6B DKK | 3.6 | 25.4 | 13.3 | 15.9 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.3B USD | 3.1 | 30 | 12.9 | 17.7 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 2.5 | 34.9 | 12.1 | 18.9 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 1.1 | -15.7 | 16.9 | 54.8 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
39.8B CNY | 8.7 | 23.9 | 21.4 | 21.4 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
40.1B CNY | 4.1 | 23.4 | 35.1 | 35.1 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
828.9B JPY | 6.4 | 46.9 | 22.1 | 30 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
